Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 16, 2024$11.35
P/E Ratio
N/A
Market Cap
$1.24B
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Overview
Trading Information
Company